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I N T R O D U C T I O N  A N D  R A T I O N A L E 




The liver is the largest internal organ in the body and it has several unique functions. These 
include synthesis of clotting factors involved in coagulation and fibrinolysis,1 carbohydrate 
and lipid metabolism, detoxification, and bile production that is essential for absorption of 
fat and other lipophilic nutrients. A well-functioning liver is therefore pivotal for human’s 
well-being and survival.2,3 Acute and chronic liver failure represent major hurdles worldwide 
resulting over 1 million deaths a year.4,5 In developing countries viral infections such as 
hepatitis A, B, and E are the predominant causes of liver disease.6,7 In contrast, the most 
common etiologies of cirrhosis in western societies are hepatitis C virus infection (HCV), 
excessive alcohol intake, genetic and inherited disorders, autoimmune conditions, and non-
alcoholic fatty liver diseases (NAFLD).5,8 Although cirrhotic patients can be asymptomatic, 
progressive deterioration may lead to the development of end stage liver disease (ESLD). 
ESLD is associated with severe complications including portal hypertension, ascites, hepatic 
encephalopathy,5 and development of hepatocellular carcinoma (HCC). HCC has a 5-year 
cumulative risk of 15% and 10% in endemic areas and developed countries, respectively.9,10 
In fact, HCC is responsible for 50% to 70% of liver-related mortality in patients with 
compensated cirrhosis.11,12 
 
Despite medical advances, partial liver resection and liver transplantation are the only 
curative options for patients with end stage acute or chronic liver failure, or cancer of the 
liver. However, postoperative complications still occur in many patients 13-15 because the 
liver remnant or grafts are too small or of poor quality to maintain the synthetic, excretory 
and detoxifying functions of the liver.16,17 Consequently, multiple organ failure, sepsis, and 
death can occur within days after surgery 17,18 unless prompt and sufficient liver 
regeneration occurs. 
 
Liver regeneration starts immediately following partial liver resection.19 Hepatocyte 
proliferation terminates within days in humans.3 However, Kele and associates20 showed 
that the remnant liver did not regenerate to its preoperative total liver volume after six 
months of surgery. The mechanism of liver regeneration has been studied extensively,21 yet 
little is known about factors promoting tissue repair and liver regeneration in humans 
following surgical procedures involving the liver.21,22 Studies in rodents such as mice show 
that blood platelets play a pivotal role in liver regeneration.23-26 Induction of thrombocytosis 
by administration of a single dose of thrombopoietin or by splenectomy promoted liver 
regeneration.23 Conversely, antibody-induced depletion of platelets and inhibition of platelet 
function using clopidogrel, a P2Y12 receptor blocker significantly reduced proliferation of 
hepatocytes.23-26 Also, transfusion of platelets or platelet-rich plasma promotes liver 
regeneration in mice.27,28  
 
Although the exact mechanism of platelet-mediated liver regeneration is yet to be 
determined, there is evidence that platelet derived growth factors and serotonin, which are 
I N T R O D U C T I O N  A N D  R A T I O N A L E 




stored within the platelet granules, play a key role in proliferation of hepatocytes.26,29 
Nevertheless, the role of platelets and bioactive molecules released by platelets in 
regeneration in humans is incompletely understood. 
 
HEMOSTASIS IN PATIENTS WITH CIRRHOSIS AND HEPATOCELLULAR CARCINOMA 
 
Given the critical role of liver in coagulation, fibrinolysis, and platelet metabolism,1 patients 
with ESLD frequently have substantial abnormalities in their hemostatic system. 
Conventional coagulation assays such as the prothrombin time (PT) / international 
normalized ratio (INR) and activated partial thromboplastin time (APTT) are very often 
prolonged in patients with liver disorders reflecting hypocoagulability in these patients.30 
However, conventional coagulation tests are poor predictors of bleeding in patients with liver 
disease.30,31 In fact, PT and APTT assays may not accurately reflect the hemostatic status 
since these assays only measure the pro-coagulant activity and ignore the natural anti-
coagulant systems,30,32 Importantly, many centers tend to correct these in vitro measures 
prophylactically prior to or during invasive procedures, exposing the patients to transfusion-
related risks.33-35 In addition, the incorrect assumption that patients with liver disease are 
“auto-anticoagulated” is (partly) based on wrongful interpretation of routine hemostasis 
tests.36,37 In fact, patients with ESLD are at risk for both bleeding and thrombotic 
complications.  
 
Although cirrhotic patients commonly have a decreased platelet count,38,39 the development 
of HCC in these patients is associated with elevated platelet count.40-42 Given the interaction 
between the cancer and platelets and the increased risk of VTE in patients with HCC,44,45 
elevated platelet counts in cirrhotic patients in the presence of HCC might be considered a 
paraneoplastic manifestation of HCC.41,43 In fact, thrombotic complications are a major 
cause of death in patients with cancer.46 Yet, little is known about the interaction between 
the platelets and HCC in the presence of cirrhosis.47 In animal models, it has been shown 
that circulating platelets take up and sequester angiogenesis regulators in the presence of a 
microscopical (<1mm) human tumor.48 A recent study in humans showed that angiogenic 
proteins were elevated in platelets from patients with colorectal cancer,49 and platelet levels 
of these proteins were independent predictors of the presence of a malignancy. It has been 
established that platelet-induced angiogenic molecules are involved in extra-hemostatic 
platelet effects such as liver regeneration, tumor development and progression, and 
inflammation.50 However, it is not clear if the development of HCC in cirrhotic patients 
affects platelet biology or the levels of bioactive molecules that are stored within platelet 
granules. 
 
I N T R O D U C T I O N  A N D  R A T I O N A L E 




PREDICTORS OF OUTCOME FOLLOWING LIVER SURGERY 
 
After  liver  surgery,  all  liver  function tests  (LFTs)  may  be  abnormal  including  aspartate  
aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, 
antithrombin, PT / INR, and gamma-glutamyltransfrase (GGT).51,52 Hence, LFT 
derangements may reflect physiologic changes rather than pathologic conditions following 
procedures involving the liver. Nevertheless, LFTs may predict morbidity and mortality 
beyond a certain threshold value at a certain time point following liver surgery.15,53 As such, 
total bilirubin, PT/INR, albumin, antithrombin (AT), AST, ALT, and clinical signs such as 
ascites and encephalopathy have been consistently used in the literature to predict 
outcomes following partial liver resection and liver transplantation.15,17,53 Also blood platelet 
number decreases transiently following procedures involving the liver. Given the key role of 
platelets in liver regeneration,26,54 immediate postoperative platelet count may accurately 
predict postoperative outcomes. 
 
Contrary to other LFTs, an elevated (i.e., more deviated from the normal) GGT has shown to 
be associated with an improved hospital survival following surgical correction of a ruptured 
abdominal aortic aneurysm.55 However, in the general population, a chronically elevated 
GGT is associated with an elevated all-cause mortality related to cardiovascular disease, 
metabolic syndrome and cancer.56-59 GGT is a sensitive test of liver disease regardless of its 
causes, but it lacks specificity.60,61 GGT increases following procedures that involve the liver, 
and it has been suggested as a biomarker of biliary epithelial injury.62 Yet, little is known 
about the clinical relevance of elevated GGT following liver surgery. 
 
AIMS OF THE THESIS 
 
This thesis consists of clinical and pre-clinical research that aims to gain better 
understanding of factors influencing the outcome of liver surgery and the paradoxical role of 
GGT following liver transplantation and surgery. In addition, two studies evaluate the impact 
of HCC development on hemostasis in cirrhotic patients. 
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